Catalog No.: PC-72663Not For Human Use, Lab Use Only.
Enavogliflozin (DWP16001, GCC5694A) is a potent and selective sodium glucose co-transporter 2 (SGLT-2) inhibitor with IC50 of 0.46 nM (hSGLT2), > 700-fold selectivity against SGLT1.
Enavogliflozin (DWP16001, GCC5694A) is a potent and selective sodium glucose co-transporter 2 (SGLT-2) inhibitor with IC50 of 0.46 nM (hSGLT2), > 700-fold selectivity against SGLT1.
GCC5694A exhibited activity comparable to that of dapagliflozin.
Oral administration of GCC5694A (0.1–1 mg/kg) increased urinary glucose excretion in a dose-dependent manner.
In STZ-induced type 1 diabetic rats and type 2 diabetic db/db mice, repeated administration of GCC5694A (0.05–0.5 mg/kg) for 5 weeks significantly reduced the levels of hemoglobin A1c (HbA1c) and blood glucose.
